- More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. Skin cancer is the fourth most common cancer worldwide.(1)
- Melanoma is the most aggressive skin cancer. For patients with early stage and localized melanoma the survival rate is 99%; yet when melanoma has metastasized it is more resistant to current therapies and the survival rate drops to 15-20%. Progression from early to metastatic stages can occur in months, making the prompt diagnosis of melanoma particularly important.(2)
- Tissue biopsy is the only definite diagnostic test for skin cancer. With the increasing demand for quality healthcare globally and increased health screening, the number of pathology samples to be analyzed is also increasing. Pathology experts are required to review non-cancerous specimens in more than 90% of cases.
- The number of practicing pathologists retiring coupled with the years of practice required to achieve an expert level of competency is causing a drastically increasing shortage of expert pathologists worldwide.(8) Patient care is in jeopardy because specimen volume has risen by more than 40% while the number of professionals in the pathology field has declined.
- Delayed responses and the high cost of pathologist opinions result in reduced time to implement proper care at the early stages of disease when the tumor is likely to respond to treatment.
- Solutions helping to instantaneously differentiate benign neoplasms from potentially cancerous lesions can radically increase throughput, shorten response times and reduce costs.
- Access to expert pathology opinions is limited in low-income countries, with less than 30% having access to pathology services in the public sector as compared to more than 90% in high-income countries.(1) Applying digital pathology and AI algorithms to cancer diagnostics is the only viable option to improve access.
- According to studies in the U.S., pathologists disagree on a diagnose in 20-25% of cases on average, particularly in early stages when the case is not clear-cut, which generates demand for second opinions and expert consultations worldwide.(4)
- Diagnostic errors contribute to approximately 10% of patient deaths and are the leading cause of medical malpractice payouts.(5)